The article examines the epidemiology of imported and locally acquired dengue in Australia from 2012 to 2022. It highlights the success of the Wolbachia mosquito population replacement method in reducing local dengue transmission, particularly in northern Queensland. Between 2012 and 2022, 13,343 dengue cases were reported in Australia, with 94.2% being imported, 4.4% locally acquired, and 1.4% with unknown origin. Locally acquired cases declined from a peak of 236 in 2013 to zero in 2021–2022. Imported dengue cases were primarily acquired in Southeast Asia, Southern and Central Asia, and Oceania. Indonesia and Thailand were the top acquisition countries. DENV-2 and DENV-1 were the predominant serotypes. The study shows that imported dengue trends reflect Australian travel patterns and local epidemiology in endemic countries. The implementation of Wolbachia in northern Queensland significantly reduced local dengue transmission. The study also discusses the impact of the COVID-19 pandemic on dengue transmission, with a decrease in imported cases during 2020 and 2021 due to border closures, followed by an increase in 2022. The success of the Wolbachia method in Australia has implications for other non-endemic regions with competent mosquito vectors. The study also highlights the importance of dengue surveillance and the need for continued monitoring of areas with potential for local transmission. The findings emphasize the value of Australian dengue surveillance in providing sentinel information on circulating dengue serotypes and outbreaks in acquisition countries. The study also discusses the role of dengue vaccines in reducing the burden of dengue in endemic areas, although their use in travellers is unclear. The study concludes that the success of the Wolbachia method in interrupting local dengue transmission in Australia is encouraging for other non-endemic settings. The study also highlights the importance of considering country-specific dengue epidemiological trends when assessing travel-associated health risks for travellers.The article examines the epidemiology of imported and locally acquired dengue in Australia from 2012 to 2022. It highlights the success of the Wolbachia mosquito population replacement method in reducing local dengue transmission, particularly in northern Queensland. Between 2012 and 2022, 13,343 dengue cases were reported in Australia, with 94.2% being imported, 4.4% locally acquired, and 1.4% with unknown origin. Locally acquired cases declined from a peak of 236 in 2013 to zero in 2021–2022. Imported dengue cases were primarily acquired in Southeast Asia, Southern and Central Asia, and Oceania. Indonesia and Thailand were the top acquisition countries. DENV-2 and DENV-1 were the predominant serotypes. The study shows that imported dengue trends reflect Australian travel patterns and local epidemiology in endemic countries. The implementation of Wolbachia in northern Queensland significantly reduced local dengue transmission. The study also discusses the impact of the COVID-19 pandemic on dengue transmission, with a decrease in imported cases during 2020 and 2021 due to border closures, followed by an increase in 2022. The success of the Wolbachia method in Australia has implications for other non-endemic regions with competent mosquito vectors. The study also highlights the importance of dengue surveillance and the need for continued monitoring of areas with potential for local transmission. The findings emphasize the value of Australian dengue surveillance in providing sentinel information on circulating dengue serotypes and outbreaks in acquisition countries. The study also discusses the role of dengue vaccines in reducing the burden of dengue in endemic areas, although their use in travellers is unclear. The study concludes that the success of the Wolbachia method in interrupting local dengue transmission in Australia is encouraging for other non-endemic settings. The study also highlights the importance of considering country-specific dengue epidemiological trends when assessing travel-associated health risks for travellers.